Morchella polysaccharide ameliorates myocardial infarction inflammation in mice through increasing gut microbiota-derived 12-HEPE.
Does Morchella polysaccharide ameliorate myocardial infarction injury and inflammation in mice?
Morchella polysaccharide is being investigated in a preclinical mouse model for its potential to ameliorate myocardial infarction injury and inflammation via modulation of gut microbiota.
Myocardial infarction (MI) initiates robust inflammatory responses. While moderate inflammation facilitates the clearance of necrotic debris, sustained inflammation promotes fibrosis and exacerbates MI progression. Fungal polysaccharides have shown significant anti-inflammatory activity, but role of Morchella polysaccharide (MCP) in modulating MI-associated inflammation remains unclear. In this study we investigated whether MCP ameliorated myocardial infarction injury and elucidated the underlying mechanisms focusing on the gut microbiota and associated metabolites. MI mice were established in mice by permanent ligation of the left anterior descending (LAD) coronary artery. MCP (200, 600 mg·kg
Su et al. (Fri,) conducted a other in Myocardial infarction. Morchella polysaccharide (MCP) was evaluated on Myocardial infarction injury and inflammation. Morchella polysaccharide ameliorates myocardial infarction inflammation in mice through increasing gut microbiota-derived 12-HEPE.